NCT04983810View on ClinicalTrials.gov

A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

July 12, 2021

Primary Completion Date

April 30, 2025

Study Completion Date

June 30, 2025

Conditions
Solid Tumor, AdultLymphoma
Interventions
DRUG

Fadraciclib

Fadraciclib is a highly selective, orally- and intravenously- available, 2nd generation amino-purine inhibitor of CDK2 and CDK9.

Trial Locations (4)

77030

RECRUITING

MD Anderson Cancer Center, Houston

91010

RECRUITING

City of Hope, Duarte

Unknown

RECRUITING

Seoul National University Hospital, Seoul

RECRUITING

Hospital Universitario Vall d'Hebron, Barcelona

Sponsors
All Listed Sponsors
lead

Cyclacel Pharmaceuticals, Inc.

INDUSTRY

NCT04983810 - A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma | Biotech Hunter | Biotech Hunter